Print this page    •   Back to Web version of article

Changes in Viramune XR Tablets for Kids

By Enid Vázquez

January/February 2013

The FDA approved changes to the Viramune (nevirapine) Extended-Release (XR) tablet label to include the 100-mg tablet and dosing information for children ages six to 18 years. Previously, only 200-mg immediate release (IR) tablets or 400-mg extended release (XR) tablets were available.

The Dosage and Administration section was updated to include the following:

No recommendations were made regarding substitution of four Viramune XR 100-mg tablets for one Viramune XR 400-mg tablet.

Dosing information in the Pediatric Patients section states that pediatric patients may be dosed using Viramune XR 400-mg or 100-mg tablets, still twice daily (adults get a once-daily dose with either IR or XR tablets). They must also follow the same special directions that adults do for taking Viramune: a lead-in dose of one 200-mg IR tablet a day for two weeks before starting their full dose (critical for preventing rash, which can be dangerous). The total daily dose should not exceed 400-mg for any patient.


Got a comment on this article? Write to us at publications@tpan.com.




This article was provided by Positively Aware. It is a part of the publication Positively Aware. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/70283/changes-in-viramune-xr-tablets-for-kids.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.